ENGINEERED BOTULINUM NEUROTOXIN
Abstract Botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B(B-H,), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain I, Vlll8M; Y1183M; E119IM; E11911;E9IQ; E119IT; S1199Y; S11...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English |
Published |
10.10.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract Botulinum neurotoxin (BoNT) polypeptides with a modified receptor binding domain of Clostridial botulinum serotype B(B-H,), comprising one or more substitution mutations corresponding to substitution mutations in serotype B, strain I, Vlll8M; Y1183M; E119IM; E11911;E9IQ; E119IT; S1199Y; S1199F; S1199L; SI 20 IV; or combinations thereof. Specific combination mutations include El 191M and SI 199L, El 191M and SI 199Y, El 191M and SI 199F, El 191Q and SI 199L, El 191Q and S 1199Y, or E 1191 Q and S 1199F. Other substitution mutations are also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical compositions, and methods of using the same are also disclosed. |
---|---|
Bibliography: | Application Number: AU20180200409 |